Company Encyclopedia
View More
name
Evogene
EVGN.US
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance.
1.946 T
EVGN.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking165/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE667.67%A
    • Profit Margin-34.29%E
    • Gross Margin49.68%B
  • Growth ScoreB
    • Revenue YoY7.19%C
    • Net Profit YoY88.31%A
    • Total Assets YoY-34.97%E
    • Net Assets YoY40.97%A
  • Cash ScoreC
    • Cash Flow Margin-291.60%D
    • OCF YoY7.19%C
  • Operating ScoreD
    • Turnover0.24D
  • Debt ScoreB
    • Gearing Ratio33.86%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Evogene Ltd. unveils company presentation highlighting proprietary innovation in real-world challenges

    Evogene Ltd. has unveiled a company presentation detailing its proprietary algorithms and technological capabilities to tackle real-world challenges. The presentation emphasizes factors like synthetic accessibility, chemical stability, molecular weight, and machine learning models such as QSAR. This highlights Evogene's innovative approach in its field. The full presentation is available online, and the news brief was generated by Public Technologies using AI.

    Reuters·
    US
    EVGN
    +3.77%
    Reuters·
    US
    EVGN
    +3.77%

    Evogene Reports Q3 2025 Financial Results Amid Strategic Shift

    Evogene Ltd. announced its Q3 2025 financial results, highlighting a strategic shift towards computational chemistry and small molecule design. The company reduced operating expenses and operating loss through organizational realignment and cost-reduction measures. Despite decreased revenue, the sale of Lavie Bio’s assets and MicroBoost AI improved its cash position. Analysts rate the stock as Hold with a $1.00 target, noting weak financial performance and high leverage. Evogene focuses on its ChemPass AI platform to drive innovation in pharma and agriculture.

    Tip Ranks·
    US
    EVGN
    +3.77%
    Tip Ranks·
    US
    EVGN
    +3.77%

    Israeli biotech firm Evogene's Q3 revenue misses estimates due to reduced seed sales

    Israeli biotech firm Evogene's Q3 revenue missed estimates due to reduced seed sales from Casterra. Despite this, operating expenses decreased significantly due to a strategic transition and cost-reduction plan, leading to improved net income from discontinued operations after asset sales. The company plans to maintain reduced expenses and generate future revenue through Casterra initiatives. The only analyst rating is "buy," with a 12-month price target of $2.50, 53.2% above the current price.

    Reuters·
    US
    EVGN
    +3.77%
    Reuters·
    US
    EVGN
    +3.77%

    Evogene posts $3.5 million revenue and $8.8 million operating loss for first nine months of 2025

    Evogene Ltd. reported a $3.5 million revenue and an $8.8 million operating loss for the first nine months of 2025, down from a $15.3 million loss in the same period of 2024. The decrease in revenue was mainly due to lower revenue from AgPlenus and a one-time payment from Bayer in 2024, partially offset by increased seed sales from Casterra. The company realigned its organization and reduced costs, focusing on computational chemistry and generative design of small molecules.

    Reuters·
    US
    EVGN
    +3.77%
    Reuters·
    US
    EVGN
    +3.77%

    Evogene Q3 2025 Earnings Preview

    Evogene (EVGN) will announce Q3 earnings on November 20th before market open. The consensus EPS estimate is -$0.41 (+68.7% Y/Y) and the consensus revenue estimate is $0.65M (-63.9% Y/Y). Over the last 2 years, EVGN has beaten EPS estimates 63% of the time and revenue estimates 50% of the time.

    MSN·
    US
    EVGN
    +3.77%
    MSN·
    US
    EVGN
    +3.77%
    © 2025 Longbridge｜Disclaimer